Clinical Trial Update: Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder [Phase 4]

View source ↗

Summary

Phase 4 study investigating predictors of response to augmentation with ziprasidone (Geodon) in major depressive disorder, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder

Drugs mentioned

• Geodon (Ziprasidone)

Snippet

Sponsor: Tufts Medical Center | Conditions: Depression, Bipolar Disorder | Phase 4 | Status: COMPLETED | Results posted: 2017-02-13